SI21171A - Uporaba sevov parapoksvirusa ovis proti fibrozi organov - Google Patents

Uporaba sevov parapoksvirusa ovis proti fibrozi organov Download PDF

Info

Publication number
SI21171A
SI21171A SI200120047A SI200120047A SI21171A SI 21171 A SI21171 A SI 21171A SI 200120047 A SI200120047 A SI 200120047A SI 200120047 A SI200120047 A SI 200120047A SI 21171 A SI21171 A SI 21171A
Authority
SI
Slovenia
Prior art keywords
fibrosis
preventive
medicaments
preparation
human
Prior art date
Application number
SI200120047A
Other languages
English (en)
Slovenian (sl)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of SI21171A publication Critical patent/SI21171A/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200120047A 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis proti fibrozi organov SI21171A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (1)

Publication Number Publication Date
SI21171A true SI21171A (sl) 2003-10-31

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200120047A SI21171A (sl) 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis proti fibrozi organov

Country Status (30)

Country Link
US (1) US6632647B2 (lv)
EP (1) EP1303302B1 (lv)
JP (1) JP5106736B2 (lv)
CN (1) CN1452496B (lv)
AR (1) AR028800A1 (lv)
AU (2) AU2001285827B2 (lv)
BG (1) BG107447A (lv)
CA (1) CA2415399C (lv)
CZ (1) CZ200372A3 (lv)
DK (1) DK200300014A (lv)
EE (1) EE200300019A (lv)
FI (1) FI20030038A (lv)
GB (1) GB2383752B (lv)
HK (1) HK1054330B (lv)
HR (1) HRP20030097A2 (lv)
HU (1) HU227668B1 (lv)
IL (1) IL153826A0 (lv)
LT (1) LT5064B (lv)
LU (1) LU90996B1 (lv)
LV (1) LV12991B (lv)
MA (1) MA25765A1 (lv)
MX (1) MXPA03000278A (lv)
NO (1) NO20030081L (lv)
NZ (1) NZ523535A (lv)
PL (1) PL360839A1 (lv)
RU (1) RU2003104522A (lv)
SE (1) SE0300033L (lv)
SI (1) SI21171A (lv)
SK (1) SK382003A3 (lv)
WO (1) WO2002004019A2 (lv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
WO2003050135A2 (en) 2001-12-07 2003-06-19 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
KR20180129779A (ko) 2016-02-16 2018-12-05 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 섬유화를 치료하기 위한 의약 조성물
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis;PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL329353A1 (en) * 1996-04-15 1999-03-29 Anton Mayr Novel indications for application of as a drug the agents obtained from smallpox or parapox viruses, possessing many potential ablities, capable to produce parapox immunity
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
HRP20030097A2 (en) 2005-02-28
HUP0303830A3 (en) 2004-10-28
GB2383752B (en) 2004-11-24
US20020076418A1 (en) 2002-06-20
US6632647B2 (en) 2003-10-14
MXPA03000278A (es) 2004-04-05
RU2003104522A (ru) 2004-06-27
FI20030038A (fi) 2003-03-10
CN1452496A (zh) 2003-10-29
HK1054330B (zh) 2005-07-15
EP1303302A2 (de) 2003-04-23
CA2415399C (en) 2011-11-08
AU2001285827B2 (en) 2006-11-30
PL360839A1 (en) 2004-09-20
IL153826A0 (en) 2003-07-31
GB2383752A (en) 2003-07-09
HU227668B1 (en) 2011-11-28
JP5106736B2 (ja) 2012-12-26
DK200300014A (da) 2003-03-07
CA2415399A1 (en) 2003-01-08
LT5064B (lt) 2003-11-25
CN1452496B (zh) 2012-10-10
HK1054330A1 (en) 2003-11-28
SE0300033D0 (sv) 2003-01-10
WO2002004019A3 (de) 2002-08-01
EP1303302B1 (de) 2009-10-14
LT2003008A (en) 2003-07-25
MA25765A1 (fr) 2003-04-01
NO20030081D0 (no) 2003-01-08
GB0302629D0 (en) 2003-03-12
WO2002004019A2 (de) 2002-01-17
HUP0303830A2 (hu) 2004-04-28
CZ200372A3 (cs) 2003-05-14
NZ523535A (en) 2004-12-24
SE0300033L (sv) 2003-03-10
AU8582701A (en) 2002-01-21
JP2004502741A (ja) 2004-01-29
BG107447A (bg) 2003-09-30
AR028800A1 (es) 2003-05-21
LU90996B1 (en) 2003-01-08
NO20030081L (no) 2003-01-08
SK382003A3 (en) 2003-07-01
LV12991B (en) 2003-08-20
EE200300019A (et) 2004-10-15

Similar Documents

Publication Publication Date Title
SI21171A (sl) Uporaba sevov parapoksvirusa ovis proti fibrozi organov
JP5950964B2 (ja) 臓器線維形成に対するパラポックスウイルスovis株の使用
Shipkowitz et al. Antiviral activity of a bis-benzimidazole against experimental rhinovirus infections in chimpanzees
WO2006099376A1 (en) Dragon's blood anti-viral materials and methods
US20090076132A1 (en) Antiviral compositions and methods of treatment
CN113318115B (zh) 美他环素在制备防治牛副流感病毒3型病毒感染药物中的应用
CN106581052B (zh) 柠檬酸根离子和铁离子在抑制rna病毒中的应用
WO2022000167A1 (zh) 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
WO2004101621A1 (fr) Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci
US11591616B1 (en) Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
US20230226136A1 (en) A synergistic formulation for management of respiratory pathogens including coronaviruses
Filin et al. Experimental evaluation of the activity of the product meflochine against coronavirus SАRS-CoV-2
WO2022034557A1 (en) Intravenous and oral inhalation anti-viral compositions and methods
CN118021824A (zh) 一种抗马立克氏病病毒的药物以及蒲公英甾醇或阿魏酸及其联合使用在药物制备中的应用
CN117357573A (zh) 一种呼吸道抗菌鼻用软膏及其制备方法
CN113827614A (zh) 制备药用混合物的方法、所得药用混合物及其医药用途
Yang et al. Type I interferons triggered through the TLR3-TRIF pathway control
İnan SOME DRUGS USED IN THE COVID-19 OUTBREAK AND TREATMENT
WO2016133560A1 (en) Recombinant human cc10 protein for treatment of influenza and ebola

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20070226